Podcasts about cancer care

WBBM Noon Business Hour host Rob Hart sits down with Dr. Kevin King of City of Hope & Dr. Jose Sanchez of Humboldt Park Health to discuss the latest advancements in cancer care, their effort to provide these services to those who need it & much more!

Episode summaryAt 32, Marcia found a lump she assumed was “nothing.” It wasn't. In quick succession came diagnosis (May 1998), surgery including mastectomy and reconstruction, and years of hormone therapy. The shock gave way to a long, messy recovery marked by anxiety, tears, and the fierce desire to “be there” for her two young sons. Yoga entered as a lifeline: first disciplined Iyengar classes that rebuilt physical strength and steadiness, then Aṣṭāṅga for rhythm, breath, dṛṣṭi, and mental focus, and eventually yoga therapy informed by the pañcamaya kośa model—meeting herself where she was, day by day.Part two of Marcia's story is even more tender: years later, her 15-year-old son, Alex, was diagnosed with high-grade osteosarcoma. Eight months of aggressive chemotherapy, limb-saving surgery, infection, and eventual amputation followed. Through sleepless hospital nights and fragile windows at home, Marcia leaned on simple, steady practices—breath, gentle movement, and the sacred ordinary of hanging laundry in the sun. Key themesThe long arc of recovery: Treatment can be quick; integration takes time. Yoga created structure (set sequences, five-breath holds) that translated into emotional steadiness.From outer strength to inner ease: As physical stability returned, so did mental clarity and emotional regulation—sthira-sukham āsanam (PYS 2.46) in action.Rituals of the ordinary: In crisis, simple routines (breathing, gentle stretches, even doing the wash) become anchors of meaning and regulation.Pañcamaya kośa self-check: How am I—body, breath/energy, mind, personality/values, and meaning? Let practice be responsive, not rigid.Caregivers need care: Five minutes of breath can change the nervous system—and the day.Post-traumatic growth: Agency (“this diagnosis won't define our life”) and community support foster resilience.Yoga therapy in oncology: Practical tools for survivors and families; thoughtful scope of practice and team-based care.Memorable moments“I was angry at the interruption to my life—I didn't want cancer to stop me from living my dharma.”“The set sequence and five breaths made Aṣṭāṅga meditative; my body knew what came next, and my mind could rest.”“Hospital life means not moving, not sleeping, not eating well. At home, a decent meal, a real bed, and a few breaths on the mat felt holy.”“Supporting my son after amputation, I realized the PT's ‘Superman' was Śalabhāsana—the same human body, different language.”Practical takeaways (for listeners)Structure regulates: A consistent class or home sequence can downshift anxiety; predictability is medicine.Five-breath rule: Linger in postures long enough to feel the pose regulate the breath (and vice versa).Honor seasons: Your practice can be Iyengar-precise one season, Aṣṭāṅga-rhythmic the next, and kośa-guided thereafter. That's yoga.Caregiver micro-practices work: Three minutes of diaphragmatic breathing between scans or consults matters.Who this episode supportsPeople navigating or recovering from cancerParents and caregivers living in medical systemsYoga teachers/therapists seeking oncology-informed, nervous-system-first approachesAnyone rebuilding identity and routine after a health crisisAbout Marcia MercierWebsite: www.marcie.yoga.com Location: North London (UK)Offerings:Weekly online Yoga for Breast Cancer (Wednesdays 09:30–10:30 UK)1:1 Yoga Therapy (online & in person)Haṭha and Vinyāsa classes (online and local studios)Contributor with Get Me Back—a cancer-recovery community offering strength training, yoga, Pilates, and on-demand classes (getmeback.uk)Resources mentionedmarcie.yoga — contact and class scheduleGet Me Back (UK): membership and on-demand support for people post-treatmentHost reflectionMarcia's story is a fierce testament to the human spirit yoked to practice. In yogic terms, she modeled tapas without self-punishment, svādhyāya without self-absorption, and praṇidhāna without passivity. This is what it looks like when philosophy leaves the page and enters a hospital ward, a nursery, a kitchen, and a yoga mat. Healing is not linear; it is rhythmic—breath by breath, five breaths at a time.Connect with The Yoga Therapy HourWebsite: TheOptimalState.comInstagram & LinkedIn: Optimal State Yoga TherapySubscribe, rate, and share if this helped you or someone you love.Content note & disclaimerThis episode includes personal experiences with cancer and hospitalization. Yoga therapy is complementary and not a substitute for medical care. Please consult your healthcare team before beginning or modifying any practice.

The future of cancer care is shifting toward earlier detection, continuous monitoring, and truly personalized treatment powered by high-quality genomic insights. In this episode, Ajay Gannerkote, President of Integrated DNA Technologies, explains how rapid advances in genomics are transforming cancer diagnosis, precision medicine, and personalized care. He describes how IDT evaluates emerging technologies by combining custom manufacturing, high-quality reagents, and deep scientific partnerships to deliver clinically meaningful insights. Ajay highlights how NGS, MRD, and multi-cancer detection are expected to accelerate over the next 3–5 years, enabling far earlier diagnosis and more precise monitoring. He also underscores the power of collaboration, shares a rare pediatric success story, and reflects on leadership principles centered on trust, innovation, and an “obligation to dissent.” Tune in and learn how the next wave of genomic innovation is bringing precision medicine within reach for patients everywhere! Resources Connect with and follow Ajay Gannerkote on LinkedIn. Follow Integrated DNA Technologies on LinkedIn and visit their website!

We are joined by two leaders from Aminex Therapeutics, Mark Burns, President & CSO, and Jeff Judson, VP of Strategic Planning & Investor Relations, to discuss the groundbreaking development of Aminex 1501, a novel cancer therapy that is transforming oncology. This conversation dives into the science behind this innovative therapy, its distinctive funding journey, the promising clinical trial results, and the collaboration with CTI. Listen now to explore the significance of FDA orphan drug designation and what it means for advancing innovative treatments for rare cancers. 00:10 Aminex 1501 is introduced, along with its mission to fight cancer by removing essential growth factors from tumors, stimulating the immune system 00:43 The drug's effectiveness across a wide range of solid tumors, showcasing its tumor-agnostic approach 01:11 Mark shares the origin of Aminex, highlighting its unique funding by angel investors outside biotech and the absence of venture capital 02:01 Why they chose CTI as a partner: technical competence, responsiveness, and Midwest values 03:18 How the therapy removes polyamines from tumors, leading to profound immune responses in animal models 04:11 The team discusses receiving FDA orphan drug designation for neuroblastoma and ongoing pediatric trials at Penn State University 05:15 Insights into the treatment of six rare childhood cancers, with a focus on improving quality of life and minimizing side effects 05:56 Breast cancer and melanoma identified as promising indications for future focus, with neuroblastoma and others also in scope 06:23 Recap of clinical trial progress and milestones  07:19 Recognition of patients as heroes in advancing cancer therapeutics 08:03 How the therapy trains the immune system to recognize and attack cancer 08:57 The inspiration behind targeting polyamines and the development of DFMO and Aminex 1501 10:00 Anecdotes about early animal studies, dramatic tumor shrinkage, and the motivation to continue research 12:13 The team's passion for improving patient outcomes and the importance of collaboration 13:00 Information for patients interested in joining trials, with details on upcoming clinics and how to find more information on clinicaltrials.gov 

Send us a textDr. Amar Rewari MD, MBA, FASTRO ( https://amarrewari.com/ ) is a physician executive and oncology leader with over 20 years of experience bridging clinical medicine, healthcare finance, and health policy.After earning his MD and MBA from Yale University, Dr. Rewari began his career in healthcare investment banking at Credit Suisse—an experience that shaped how he approaches the business and economics of healthcare.Today, Dr. Rewari leads the radiation oncology service line at Luminis Health ( https://www.luminishealth.org/en/find-a-provider/amar-rewari?language_content_entity=en ), overseeing operations and strategic growth for a program that serves more than 200 patients daily across three centers, and teaches health policy and economics as an Adjunct Assistant Professor at the Johns Hopkins School of Medicine.Nationally, Dr. Rewari serves on the Board of Directors of the American Society for Radiation Oncology ( ASTRO - https://www.astro.org/about-astro/board-and-leadership/board-of-directors/bios/amar-rewari ), where he chairs both the Health Policy Council and the Corporate Advisory Council. In these roles, he leads efforts around payment reform, advocacy, value-based innovation, and collaboration between providers and industry to advance the field of radiation oncology.Dr. Rewari is also the founder and co-host of Value Health Voices ( https://www.valuehealthvoices.com/ ), a podcast that makes health policy and economics accessible to clinicians and leaders, and Chair of the Board for the Fund for Education Abroad ( https://fundforeducationabroad.org/ ), advancing nonprofit governance and global education access for students with financial need.Featured by NBC News, TIME, Politico, and NewsNation, Dr. Rewari is driven to connect insights from the front lines of care to the broader policies shaping a smarter, fairer, and more sustainable healthcare system.#AmarRewari #RadiationOncology #LuminisHealth #FundForEducationAbroad #AmericanSocietyForRadiationOncology #ValueHealthVoices #Radiotherapy #PaymentReform #ReimbursementLevels #Medicare #AlternativePaymentModels #ValueBasedPaymentDesign #HealthPolicy #EpisodeBasedPayment #RelativeValueUnits #Coding #PriorAuthorization #FederalResearchFunding #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #STEM #Innovation #Technology #Science #ResearchSupport the show

In this episode of Lung Cancer Considered, host Dr. Stephen Liu speaks with two thoracic oncologists practicing in New Zealand—Dr. Laird Cameron from Auckland Hospital and Dr. Annie Wong from the University of Otago—about the unique challenges and approaches to lung cancer care in their island nation of 5.4 million people. The conversation explores New Zealand's healthcare coverage system, patient population characteristics including smoking rates, the current state of lung cancer screening programs, and how molecular testing is conducted for non-small cell lung cancer patients. Drs. Cameron and Wong discuss access to targeted therapies and immunotherapy, the drug approval process in New Zealand, cultural considerations and health disparities affecting lung cancer treatment, and the clinical research infrastructure available in the country. This global perspective highlights how IASLC members face different regional challenges while working toward common goals in advancing lung cancer care.

Beat Cancer host Chris Joyce speaks with Reese Olander, Managing Executive Director of Development for the UC Davis Comprehensive Cancer Center, about common misconceptions surrounding philanthropic giving, the various avenues available for giving, and, most importantly, how philanthropy can extend and enhance cancer care and treatment for our patients. You can learn more about available opportunities here. To learn more about the UC Davis Comprehensive Cancer Center, visit https://health.ucdavis.edu/cancer/

Managing prostate cancer today means balancing cancer control with overall health and wellbeing. This episode explores how chronic conditions, frailty, and quality-of-life considerations shape treatment choices from localised to advanced disease. Authors discuss why survival data has shifted the rationale for radical interventions, the complexities introduced by systemic therapy, and why assessing physiological age matters more than chronological age. Discover how comprehensive geriatric assessment supports personalised care, and how holistic, multidisciplinary decision-making can align treatment with life expectancy, patient preference, and independence. This podcast is published open access in Oncology and Therapy and is fully citeable. You can access the original published podcast article through the Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-025-00407-6. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Oncologist and health care executive Yousuf Zafar discusses his article, "When cancer costs too much: Why financial toxicity deserves a place in clinical conversations." Yousuf explains the concept of "financial toxicity," a severe burden caused by both direct medical bills and indirect costs (like time off work or child care) associated with cancer treatment. He reveals the sobering statistic that over forty percent of patients deplete their savings within two years, but emphasizes that this distress is more than just a financial problem: it directly compromises treatment adherence, forcing some to skip appointments or forgo prescriptions. Yousuf highlights the critical lack of cost transparency in oncology and makes the case for why clinicians must proactively screen for financial strain just as they would for physical side effects. Discover why these difficult conversations about the cost of cancer are essential for improving patient outcomes and quality of life. Our presenting sponsor is Microsoft Dragon Copilot. Want to streamline your clinical documentation and take advantage of customizations that put you in control? What about the ability to surface information right at the point of care or automate tasks with just a click? Now, you can. Microsoft Dragon Copilot, your AI assistant for clinical workflow, is transforming how clinicians work. Offering an extensible AI workspace and a single, integrated platform, Dragon Copilot can help you unlock new levels of efficiency. Plus, it's backed by a proven track record and decades of clinical expertise, and it's part of Microsoft Cloud for Healthcare, built on a foundation of trust. Ease your administrative burdens and stay focused on what matters most with Dragon Copilot, your AI assistant for clinical workflow. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

Please visit answersincme.com/860/IME-69386-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in NSCLC discuss how to harness targeted ADCs with practical, case-based insights to personalize care and improve outcomes in advanced lung cancer. Upon completion of this activity, participants should be better able to: Interpret the latest clinical trial data for approved and emerging antibody-drug conjugates (ADCs) in NSCLC; Recognize biomarker-driven strategies to guide treatment management in patients with NSCLC; and Apply evidence-based strategies for the individualized management of patients with NSCLC receiving ADC therapy.

About Ajay Gannerkote:Ajay Gannerkote is a global healthcare leader with deep experience spanning life sciences, medical devices, and healthcare services. Now serving as president of Integrated DNA Technologies (IDT), a Danaher company, he oversees the organization's growth and strategic direction from Redwood City, California. Before IDT, he led Siemens Healthineers' global ultrasound business as president and head, steering a complex, vertically integrated operation across more than 30 countries. Under his leadership, the business moved from negative growth and margins to strong, sustainable performance, becoming an industry leader in AI-driven clinical technology. Prior to that, he served as Director at KKR Capstone, where he co-led healthcare operations, drove large-scale transformations for portfolio companies, and created significant enterprise value across services and medical device sectors. Ajay spent more than a decade at McKinsey & Company as a partner in the Global Medical Products practice, advising Fortune 500 companies on product development, commercialization, operations, growth strategy, and large-scale turnarounds. Earlier in his career, he held leadership roles at Federal-Mogul, Cambridge Technology Partners, and Infosys, building a foundation in operations, technology, and global business integration. He holds an MBA in Corporate Strategy and Marketing from the University of Michigan's Ross School of Business and a bachelor's degree in Electronics and Telecommunications Engineering from the University of Mysore.Things You'll Learn:Genomic technologies, such as NGS and MRD, are enabling earlier cancer detection, sometimes years ahead of traditional diagnostic methods. This early visibility allows clinicians to intervene sooner and build more personalized treatment strategies.Precision medicine is rapidly maturing as high-quality genomic data becomes central to diagnosis, monitoring, and therapy planning. The next era of oncology will rely heavily on personalized, data-driven decisions.Collaboration across industry, researchers, and regulatory bodies is essential for breakthrough medical innovations. A recent case of a rare disease demonstrates how a coordinated effort can compress the journey from diagnosis to therapy into just a few months.Custom manufacturing and high-quality reagents are critical enablers of clinically reliable genomic insights. Tailored solutions allow researchers and clinicians to analyze tumor-specific markers with greater accuracy and confidence.Strong leadership in genomics requires trust, transparency, and a willingness to challenge assumptions. Ajay's “obligation to dissent” principle encourages continuous innovation and pushes teams to think beyond the status quo.Resources:Connect with and follow Ajay Gannerkote on LinkedIn.Follow Integrated DNA Technologies on LinkedIn and visit their website.

Healthcare innovation in cancer care often means new drugs or breakthrough therapies. But as Othman Laraki, co-founder and CEO of Color Health, explains, the most powerful impact comes from making proven tools work for everyone. In this episode, Othman shares his journey from Google and Twitter into healthcare, driven by his family's history with breast cancer. He describes how Color Health evolved from genetic testing into a full “virtual cancer clinic” that addresses screening, early detection, treatment navigation, and survivorship. We discuss the challenges of healthcare's multi-payer system, why distribution costs outweigh lab costs, and how focusing on efficiency and simplicity leads to better outcomes. Othman also reflects on the future of AI in medicine, from reducing friction in basic care to scaling clinical judgment across populations.     Music Credit: "Upbeat Corporate" by Music For Creators is licensed under CC BY (Creative Commons Attribution) via freemusicarchive.org.

Jim Foote, Co-Founder and CEO of First Ascent Biomedical, is changing the standard of care for cancer treatment from 'try and hope' to 'test and treat'. The First Ascent platform combines functional drug testing of fresh biopsies, genomic sequencing, and an AI engine to assess a large panel of drugs and identify the most likely to be effective. Clinical data show a high correlation between how cancer cells respond in the lab test and how patients respond to the same drug, and is seen as a treatment guide for refractory cancer patients to identify novel drug combinations. Jim explains, "Fundamentally speaking, if we look at everybody on this planet from a DNA and RNA perspective, there are 8 billion people, and each one of us is different from the others due to our DNA and RNA. So if we acknowledge that biologically we're all different, then the problem that we're trying to solve is if we're all different, why are we treating each patient with the same standard of care? A process that has existed for a hundred years, and again, they've made substantial advancements, but functional precision medicine is really an opportunity to move away from a standard that's based on the laws of averages and really treat people based on an individual level, developed by results that come from their individual biology."  "In oncology, these practices and standards have been developed over decades. And in some situations, some of these cancer protocols haven't been updated in decades. There had been continual advancements in things like immunotherapy. What I'll say is that in oncology, they're always looking for the silver bullet. It's in the genome, it's in a biomarker, it's in immuno-oncology, it's in an organoid, it's in all of those types of things. So they have always tried to find that silver bullet. Fundamentally, what we do in First Ascent is that we believe that we have enough bullets, per se. We have enough drugs, per se. We're just not using them in the right ways. " #FirstAscentBiomedical #Cancer #Oncology firstascentbiomedical.com Download the transcript here

Jim Foote, Co-Founder and CEO of First Ascent Biomedical, is changing the standard of care for cancer treatment from 'try and hope' to 'test and treat'. The First Ascent platform combines functional drug testing of fresh biopsies, genomic sequencing, and an AI engine to assess a large panel of drugs and identify the most likely to be effective. Clinical data show a high correlation between how cancer cells respond in the lab test and how patients respond to the same drug, and is seen as a treatment guide for refractory cancer patients to identify novel drug combinations. Jim explains, "Fundamentally speaking, if we look at everybody on this planet from a DNA and RNA perspective, there are 8 billion people, and each one of us is different from the others due to our DNA and RNA. So if we acknowledge that biologically we're all different, then the problem that we're trying to solve is if we're all different, why are we treating each patient with the same standard of care? A process that has existed for a hundred years, and again, they've made substantial advancements, but functional precision medicine is really an opportunity to move away from a standard that's based on the laws of averages and really treat people based on an individual level, developed by results that come from their individual biology."  "In oncology, these practices and standards have been developed over decades. And in some situations, some of these cancer protocols haven't been updated in decades. There had been continual advancements in things like immunotherapy. What I'll say is that in oncology, they're always looking for the silver bullet. It's in the genome, it's in a biomarker, it's in immuno-oncology, it's in an organoid, it's in all of those types of things. So they have always tried to find that silver bullet. Fundamentally, what we do in First Ascent is that we believe that we have enough bullets, per se. We have enough drugs, per se. We're just not using them in the right ways. " #FirstAscentBiomedical #Cancer #Oncology firstascentbiomedical.com Listen to the podcast here

Welcome back to the Pear Healthcare Playbook! Today we're thrilled to sit down with Othman Laraki, Co-founder and CEO of Color Health, a company reinventing cancer care through a virtual-first, end-to-end model. Othman has spent his career at the intersection of technology and healthcare—from helping build Chrome at Google to leading product at Twitter to founding Color, where he now focuses on expanding access to high-quality cancer prevention, screening, and treatment.In this episode, we explore how Color got started, what the team learned transitioning from genomics into full-stack care delivery, and why reducing friction across the care pathway is critical for improving outcomes. We dive into how Color's model works across the entire cancer journey, how the company thinks about system-level change and distribution, and how AI—through collaborations with OpenAI and Google Cloud—is powering new capabilities for patients and clinicians.

GCI Health, Fersen and Fierce Pharma, hosts Ryan Kurzman and Wendy Lund explore the fast-shifting landscape of cancer care with Pam Traxel of the American Cancer Society Cancer Action Network. Traxel outlines the growing complexity facing patients—from navigating an expanding range of treatment options to managing rising costs—and explains why access to reliable insurance remains one of the most urgent challenges. As she notes, even with groundbreaking innovation, patients still struggle with affordability, systemic barriers and an overwhelming amount of information that is not always credible or tailored to their specific diagnosis. The conversation also examines the evolving role of patient advocacy and the partnerships needed to drive meaningful change. Traxel emphasizes the importance of integrating lived experiences into policy, improving the credibility of patient-facing communication and strengthening early, ongoing collaboration between biopharma, policymakers and advocacy organizations. She also highlights two top priorities for U.S. cancer policy by 2030: reducing out-of-pocket costs and improving nationwide screening rates. For healthcare and life sciences professionals seeking deeper insight into how access, innovation and policy must intersect to improve patient outcomes, this is a must-listen episode.See omnystudio.com/listener for privacy information.

Last week, the Beacon hospital became the first hospital in Ireland or the UK and only the 5th in Europe, to treat a patient using Varian's new RapidArc Dynamic technology. It is an advancement in radiotherapy technology for cancer care that improves precision, reduces treatment time, and lowers radiation exposure to surrounding healthy tissue.To explain more about the technology Pat spoke to Dr Siobhra O'Sullivan, Consultant radiation oncologist in the Beacon hospital.

Today, we'll be tackling the future of prostate cancer care. We'll be reflecting on what prostate cancer care means in practice, how the way we think about the disease is shifting, and must continue to shift in the years ahead. Scientific advances have transformed treatment in recent years, yet the lived reality of prostate cancer still extends far beyond the clinic. The disease reshapes daily life, and may leave men and their families grappling with difficult choices about how best to manage it.  Dr. Güneş Taylor is joined by three key voices at the centre of this story, following the prostate cancer journey from diagnosis through to long-term management, and asking how patients and clinicians can work together to re-think what patient-centred care could mean in the years to come. This episode is brought to you in collaboration with Bayer, part of their Prostate Cancer Perspectives series.  PP-UN-ONC-GB-0168. November 2025 References Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263 (Prostate cancer is the second most common cancer in men and the fifth leading cause of cancer death worldwide) James D, et al. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet. 2024;403(10437):1683–1722 (Each year, around 1.5 million men are diagnosed and nearly 400,000 lose their lives to the disease.1 And the numbers are rising. Diagnoses are projected to double from 1.4 million annually in 2020 to 2.9 million by 2040) Siegel RL, et al. Cancer statistics, 2022. Ca Cancer J Clin. 2022;72:7–33 (In the U.S., the proportion of men diagnosed with advanced-stage prostate cancer has doubled in recent years, due to increasing incidence of advanced-stage disease and changing guidelines regarding the prostate specific antigen screening test, implemented in the U.S. in 2012) Dodkins J, et al. Geographic, socioeconomic and demographic inequalities in the incidence of metastatic prostate cancer at time of diagnosis in England: a population based evaluation. BMJ Oncology. 2025;4:e000643 (In England, nearly one in five men only receive a diagnosis once their cancer has spread) Calvo-Schimmel A, et al. Supportive care interventions and quality of life in advanced disease prostate cancer survivors: An integrative review of the literature. Can Oncol Nurs J. 2021;31(4):412-429 (Advanced prostate cancer is often associated with long-term challenges leading to greater levels of unmet needs in supportive care) Learn more about your ad choices. Visit podcastchoices.com/adchoices

Love the episode? Send us a text!In this powerful episode of Breast Cancer Conversations, host Laura Carfang, Ed.D. sits down with philanthropist Sheri Biller of the Sheri and Les Biller Family Foundation to explore the often overlooked—but absolutely essential—role of supportive cancer care.After losing her two closest friends to breast cancer over 35 years ago, Sheri made a promise: if she ever had the resources, she would dedicate her life to improving the emotional, psychological, and practical support available to everyone facing cancer. That promise became the Biller Family Foundation and later the national coalition Together for Supportive Cancer Care.This episode dives deep into:Why the words supportive care matter—and how they differ from palliative and hospice careHow siloed hospital systems leave millions without access to emotional and psychosocial supportWhy cancer is becoming an elitist disease—and how technology and policy can fix itCaregiver burnout and why Sheri believes we need a “Teach for America” for caregiversThe shocking lack of trust, education, and information in underserved and rural communitiesWhy supportive care should be a standard of care for all life-threatening illnessesIf you're a patient, caregiver, clinician, or advocate for equity in cancer care, this conversation is a must-listen.Topics We Cover✔️ Sheri's personal story and the loss that inspired her life's work ✔️ Early challenges in cancer language, communication, and stigma ✔️ Why patients “shut down” the moment they hear the word cancer ✔️ Supportive care vs palliative care—what's the difference? ✔️ Breaking barriers for rural, underserved, and Spanish-speaking communities ✔️ Why caregivers are the next major crisis in healthcare ✔️ The need for culturally competent engagement in faith communities ✔️ Financial toxicity and the real-world burdens families face ✔️ AI and the future of early diagnosis and survivorship support ✔️ How hospitals, pharma, policy, and nonprofits are finally working togetherWhy This MattersSupportive care is more than comfort—it's critical to surviving and living with cancer. From mental health to financial navigation to caregiver support, Sheri explains how integrating supportive care into every diagnosis could transform outcomes for millions.Resources: The Biller Family Foundation: https://billerfamilyfoundation.org/Donate Here and Give The Gift of HopeSupport the showLatest News: Become a Breast Cancer Conversations+ Member! Sign Up Now. Join our Mailing List - New content drops every Monday! Discover FREE programs, support groups, and resources! Enjoying our content? Please consider supporting our work.

his episode of 'Conversations in Lung Cancer Research' hosted by Dr Alex Davis, features a discussion with Dr. Laird Cameron and Dr. Annie Wong on the current state of lung cancer care and research in New Zealand. The panel explores the challenges and disparities faced by thoracic cancer patients, particularly among the indigenous Māori population. The conversation highlights the differences between patient populations in New Zealand and Australia, the impact of rurality on cancer care, the importance of clinical trials and multinational collaborations, and the future prospects for lung cancer treatments and interventions. (00:00) Introduction and Acknowledgements(01:01) Exploring Lung Cancer in New Zealand(01:13) Meet the Experts: Dr. Laird Cameron and Dr. Annie Wong(01:48) Challenges in Lung Cancer Diagnosis and Treatment(02:44) Specialisation Stories: Why Lung Cancer?(05:20) Comparing Patient Populations: New Zealand vs. Australia(07:44) Lung Cancer Care Pathways in New Zealand(09:17) Access to Treatments and Therapies(14:57) The Role of Lung Cancer Nurses(18:21) Rural Challenges in Lung Cancer Care(22:06) Radiology and Diagnostic Delays(23:08) CTDNA and Liquid Biopsy in New Zealand(25:03) Strengths and Weaknesses in Lung Cancer Care(29:29) The Impact of Clinical Trials and TOGA(33:00) Future Interventions and Wishlists(39:33) Concluding Thoughts and Farewell

In this special session from the upcoming Prostate Summit 2.0, Dr. Eric Zielinski sits down with Dr. Geo for a rare, vulnerable and informative conversation about the why behind his life's work in prostate cancer care.Key PointsThe emotional and spiritual side of working with thousands of menWhy your why matters more than the diet, protocol, or treatment choiceThe 3 buckets of prostate cancer and why care must be personalizedHis 4 pillars of healing: lifestyle, nutrition, fitness, and stress masteryHow fasting, cruciferous veggies, mushrooms, herbs, and targeted nutraceuticals help build resilienceWhy exercise is non-negotiable, and how sitting all day harms prostate and metabolic healthThis episode blends heart, science, and practical strategy to help men live longer and better with prostate cancer.Chapters00:00 – Intro02:00 – The “why” behind Dr. Geo's work07:00 – A powerful patient story & legacy12:00 – The 3 buckets of prostate cancer18:00 – Food, fasting & “It Days”23:00 – Exercise, sitting & movement32:00 – Mushrooms, herbs & targeted nutraceuticalsFrom the upcoming Prostate Summit 2.0

Exocrine pancreatic insufficiency (EPI) affects many patients with pancreatic cancer, yet it is often overlooked in this patient populations, which leads to malnutrition. In this episode, we are joined by Dr. Shelby Yaceczko, DCN, RDN, CNSC. Yacescko is a supporting author on a recently published White Paper on the topic, and she explains what EPI is, how to screen for and treat the condition, and the essential role of dietitians in an interdisciplinary care team managing these patients.  In this episode, we discuss: How overlapping GI symptoms, lack of standardized screening tools, and limited guidelines contribute to missed diagnoses and delayed treatment What inspired the development of the White Paper How to bring EPI management into everyday practice The ready-to-use checklists, screening forms, and EHR templates within the White Paper designed to standardize treatment Hosted by Kristin Houts Click here for the shownotes. The content, products and/or services referred to in this podcast are intended for Health Care Professionals only and are not, and are not intended to be, medical advice, which should be tailored to your individual circumstances. The content is for your information only, and we advise that you exercise your own judgement before deciding to use the information provided. Professional medical advice should be obtained before taking action. The reference to particular products and/or services in this episode does not constitute any form of endorsement. Please see here for terms and conditions.

Cancer care isn't what it used to be—and that's exactly why Dr. Douglas Flora just wrote a book about it. Are you ready to understand how AI is transforming oncology? In this episode of AI and Healthcare, host Dr. Sanjay Juneja and co-hosts Dr. Douglas Flora and Dr. Deborah Pat are joined by special guest Dr. Chadi Nabhan—author, educator, and passionate advocate for cancer education—to discuss Doug's newly released book on AI in cancer care, currently #1 in oncology on Amazon. Doug wrote it because he feels "desperate" to share how dramatically cancer treatment is changing. The physicians reflect on how far oncology has come from mixing chemotherapy by hand to AI-powered precision medicine. Whether you're a healthcare professional, cancer survivor, or curious about AI in medicine, this conversation offers an honest look at where oncology is headed. New episodes every two weeks.

A doctor’s choice to walk beside patients through their hardest moments comes from a calling to serve with both skill and heart. Dr. Angela Coscio’s love for people led her from lab research to breast cancer specialization, where she witnesses courage every day. At St. Luke’s, she finds purpose in connecting deeply with patients, guiding them through treatment with compassion and individualized care. Her story reflects teamwork, devotion, and the belief that every medical decision should be a true partnership. Support The Rose HERE. Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts. Key Questions Answered Did Dr. Coscio always want to be a doctor? What path did Dr. Coscio take to become a physician? What is the role of an oncologist? How does Dr. Coscio deliver a cancer diagnosis? Why did Dr. Coscio choose oncology as her specialty? What happens at a tumor board? What does being in a comprehensive cancer center like St. Luke’s mean for patients? Are cancer treatment options personalized? How does Dr. Coscio address questions about treatment options, such as chemotherapy vs. hormone therapy? How important is the caregiver's role in cancer treatment and recovery? Does Dr. Coscio encourage second opinions? What advice does Dr. Coscio have for young women facing breast cancer? How does Dr. Coscio support patients in communicating and preparing for doctor appointments? Timestamped Overview 05:06 Interpreter Self-Doubt in Spanish 07:37 Collaborative Patient Care Discussion 10:24 St. Luke's: Team & Care 16:23 Connections in Cancer Care 19:39 Chemotherapy Decision Based on Science 20:45 Engineering Mindset Meets Oncology 25:08 Key Questions for Cancer AppointmentsSee omnystudio.com/listener for privacy information.

Upon receiving a cancer diagnosis, the first priority is to build a clinical treatment plan. But there is another equally...[…]

Upon receiving a cancer diagnosis, the first priority is to build a clinical treatment plan. But there is another equally...

How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life's experiences. In this episode, Dr Camidge sat down with Mark Socinski, MD, a medical oncologist and the executive medical director of the AdventHealth Cancer Institute in Orlando, Florida. Drs Camidge and Socinski discussed the highlights of Dr Socinski's career trajectory, as well as the personal influences that helped him arrive where he is today. Socinski describes himself as a clinician and clinical investigator with 35 years of focus on lung cancer. His role as executive director of the AdventHealth Cancer Institute involves maintaining an active clinic 1 day a week and dedicating the rest of his time to administrative duties, including recruitment and building infrastructure at the institution. In the interview, Dr Socinski explained that he was influenced to enter a career in medicine because of role of the family practitioner he knew growing up. He went on to receive undergraduate and medical degrees from the University of Vermont in Burlington. After training at Dana-Farber Cancer Institute in Boston, Massachusetts, he began his career in private general oncology practice in Vermont before seeking a more academic, subspecialty environment. He joined the University of North Carolina to concentrate on lung cancer, where he pioneered dose-escalation trials using conformal radiotherapy. Dr Socinski then described his move to the University of Pittsburgh Medical Center in Pennsylvania. There, he became the chair of the lung pathway, which limits treatment options to a single, expert-agreed standard of care based on efficacy, toxicity, and cost, thus reducing treatment heterogeneity and controlling costs. Thereafter, Dr Socinski moved to AdventHealth, attracted by the institution's goal to achieve National Cancer Institute designation and build a major cancer program. Dr Socinski shared that he finds it gratifying to care for patients and lead the development of the institute.

In this deeply inspiring episode of Keeping Abreast, Dr. Jenn Simmons welcomes Dr. Pete Sulack—chiropractor, functional medicine practitioner, and founder of Unhealthy Anonymous—for a powerful conversation about defying the odds after a terminal cancer diagnosis.Dr. Sulack shares how he turned a death sentence into a journey of hope, healing, and renewal. Through faith, nutrition, and lifestyle transformation, he reclaimed his health and now guides others to do the same. Together, he and Dr. Jenn challenge conventional cancer paradigms, exploring how mindset, personalized nutrition, and spiritual alignment can unlock the body's innate capacity to heal.This episode invites listeners to rethink what's possible in cancer recovery and beyond. It's a story of courage, resilience, and faith in both science and spirit—reminding us that health is not something we outsource but something we build from within.In This Episode, You Will Learn:How Dr. Sulack overcame a terminal brain cancer diagnosisWhy functional medicine focuses on healing the whole person, not just treating diseaseThe crucial role of personalized nutrition in recoveryHow food sensitivities and gut health shape overall wellnessWhy conventional medicine often overlooks the importance of dietThe link between faith, mindset, and the body's innate ability to healHow to take proactive responsibility for your healthWhy empowerment and education can change the cancer care paradigm

Send us a textCan spatial biology and multiplex immunofluorescence truly transform how we understand cancer?I went live from the Society for Immunotherapy of Cancer (SITC) 2025 — the 40th Anniversary Meeting to explore how spatial biology, multiplex IF, and digital pathology are coming together to redefine cancer diagnostics, research, and precision medicine.This session kicked off a weekend of cutting-edge discussions with leaders from Hamamatsu (Booth 415) and Biocare Medical (Booth 717) — two companies helping laboratories around the world embrace digital transformation and spatial imaging in oncology.

Never miss another webinar! Signup here: https://imahealth.org/weekly-webinars Learn more: https://imahealth.org/beyond-breakthroughFor more than 50 years, cancer research has chased a single dream: the breakthrough cure that would finally end the disease. But what if that search has taken us down the wrong path?In this week's episode, IMA Senior Fellow Dr. Ryan Cole and IMA Co-Founder Dr. Paul Marik sat down with filmmaker Justin Smith, director of the documentary Beyond Breakthrough, to discuss the growing movement of scientists, doctors, and patients who are redefining what healing really means.Justin shared how creating the film challenged his own assumptions about cancer and how what he discovered may reshape the way you see it too.Together, they explored:How the “breakthrough mindset” has shaped modern cancer researchThe rise of integrative, metabolic, and bioelectric therapiesWhy collaboration across disciplines may hold the key to progressWhat it means to change not just how we treat cancer, but how we understand itThis powerful conversation invited viewers to question long-held beliefs, consider new possibilities, and see cancer care through a more hopeful, holistic lens.• Donate: https://imahealth.org/donate/• Follow: https://imahealth.org/contact/• Webinar: https://imahealth.org/category/weekly-webinars/• Treatment: https://imahealth.org/treatment-protocols/• Medical Disclaimer: https://imahealth.org/about/terms-and-conditions/About IMA (Formerly FLCCC Alliance)The Independent Medical Alliance™ is a nonprofit, 501(c)(3) organization and coalition of physicians, nurses, and healthcare professionals united by a mission to restore trust and transparency in healthcare. The organization's mission is one driven by Honest Medicine™ that prioritizes patients above profits and emphasizes long-term wellness and disease prevention through empowerment of both physicians and their patients. With a focus on evidence-based medicine, informed consent, and systemic reform, IMA is driving a movement to create a more compassionate and effective healthcare system.For more information about the Independent Medical Alliance, visit www.IMAhealth.org

Jim Foote, CEO and Founder of First Ascent Biomedical a pioneer in functional precision medicine (FPM) that aims to eliminate guesswork from cancer treatment. After losing his son to cancer, Jim left a career in cybersecurity to build a data-driven platform that combines AI, robotics and real-time tumour testing to help doctors choose the right therapy for each patient. In this episode, we explore how FPM differs from traditional genomics-only testing, why tumours can respond differently even with the same patient and how AI can support rather than replace clinicians in treatment decisions. Jim also shares the economic impact of ineffective therapies, the challenges of scaling regulatory innovation in oncology, and why the future of cancer care depends on personalisation at the  cellular level.Timestamps:[00:00:45] What Is Functional Precision Medicine?[00:02:00] Jim's Personal Journey from Tech to Healthcare[00:05:50] Overcoming Regulatory and Systemic Gatekeepers[00:08:13] From Reactive Care to Personalised Treatment[00:09:08] What Lab Findings Reveal about Cancer Cells[00:10:30] Why Genomics Alone Isn't Enough[00:12:03] AI as Decision Support Not a Decision Maker[00:15:55] Cancer in Younger Populations and Misconceptions[00:20:25] Reducing Cost and Waste in Cancer Treatment[00:26:34] What Success Really Means to Jim FooteConnect with Jim - https://www.linkedin.com/in/jim-foote/ Learn more about First Ascent Biomedical - https://www.linkedin.com/company/firstascentbio/ Get in touch with Karandeep Badwal - https://www.linkedin.com/in/karandeepbadwal/ Follow Karandeep on YouTube - https://www.youtube.com/@KarandeepBadwalSubscribe to the Podcast

In today's episode, we had the pleasure of speaking with Neal Shore, MD, FACS, about the use of androgen deprivation therapy (ADT) in prostate cancer management. Dr Shore is medical director of the Carolina Urologic Research Center in Myrtle Beach, South Carolina. In our exclusive interview, Dr Shore discussed guidelines for incorporating ADT into prostate cancer clinical practice, toxicities and quality-of-life complications associated with this class of agents that health care providers should be aware of and try to mitigate, and the importance of shared decision-making between members of the multidisciplinary team, as well as patients.

On this edition of The Mark White Show, we're shining a light on the often-overlooked heroes in prostate cancer care, the caregivers. A new national survey reveals that 85% of caregivers attend medical appointments with their loved one and are four times more likely to notice treatment side effects than the patients themselves. Joining me are Dr. Daniel George, Medical Oncologist and Professor at Duke University School of Medicine, and Gina Carithers, President of the Prostate Cancer Foundation. Together, we discuss what this survey uncovers about the day-to-day realities of caregiving, how families can better navigate this journey, and the vital importance of supporting those who give so much of themselves in the process.

In this episode, host Shikha Jain, MD, speaks with Maureen McBeth, PT, MPT, CLT-LANA, about understanding individualized patient experiences with lymphedema, the value of exercise oncology and more. • Welcome to another exciting episode of Oncology Overdrive 0:14 • About McBeth 0:23 • The interview 0:52 • How did you end up in the lymphedema and cancer rehab space? 1:31 • Why is lymphedema such a big topic, especially in the breast cancer space? 3:20 • Jain and McBeth on the complexities of individual lymphedema cases, including studies on lymphatic imaging. 5:25 • Do you feel like there have been advancements in the lymphedema space that can improve our understanding of it? 9:43 • Have stigmas around lymphedema evolved over the years? 12:31 • McBeth on the educational materials available to physicians surrounding cancer-related lymphedema and prospective surveillance. 15:15 • Tell us about ImpediMed and its purpose. 17:06 • How do you incorporate these technologies into the current dialogue about more holistic care? 21:27 • Jain and McBeth on exercise oncology and its impact on overall survival. 24:22 • In ten years, what would you envision as the future of lymphedema and exercise oncology? 29:01 • If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 32:31 • How to contact McBeth 33:33 • Thanks for listening 34:20 Maureen McBeth, PT, MPT, CLT-LANA, is a licensed physical therapist and certified lymphedema therapist with over 25 years of experience in oncology rehabilitation, clinical education, and patient advocacy. She currently serves as senior medical affairs liaison at ImpediMed. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. McBeth can be reached via email mmcbeth@impedimed.com. Learn more about ImpediMed at https://www.impedimed.com/, or follow them on LinkedIn or Instagram @impedimedhealth. References • Pasket ED, et al. J Clin Oncol. 2012;doi:10.1200/JCO.2012.41.8574 • Schmitz KH, et al. J Natl Cancer Inst Monogr. 2025;doi:10.1093/jncimonographs/lgaf007. • Stout NL, et al. Cancer. 2012;doi:10.1002/cncr.27476. Disclosures: Jain and McBeth report no relevant financial disclosures.

In this episode, Ziad Hanhan, MD, hosted a discussion about lung cancer diagnosis, surgical management, and evolving treatment paradigms. Dr Hanhan is a thoracic surgeon at Hackensack Meridian Health, chairman of Surgery at Bayshore Medical Center in Holmdel, New Jersey, and chief of Thoracic Surgery at Riverview Medical Center in Red Bank, New Jersey. He was joined by: Thomas Bauer, MD, the chair of surgery at Jersey Shore University Medical Center in Neptune Township, New Jersey, and Hackensack Meridian Health School of Medicine Rachel NeMoyer, MD, a thoracic surgeon at Hackensack Meridian Health Drs Hanhan, Bauer, and NeMoyer discussed current standards and future directions in thoracic oncology, emphasizing multidisciplinary collaboration and technological innovation. The conversation opened with an overview of lung cancer epidemiology, and the experts noted that this disease remains the leading cause of cancer-related mortality in both men and women. They explained that approximately 90% of lung cancer cases are attributable to tobacco use, making cessation a key preventive measure. They also emphasized that early detection through low-dose CT screening improves outcomes when the disease is identified at an early stage. However, despite these advances, they stated that most lung cancer cases in the United States continue to be diagnosed at stage III or IV, underscoring the need for improved screening adherence. They expanded on current lung cancer screening guidelines and noted that lung cancer often presents with nonspecific symptoms, such as chronic cough or hemoptysis, and that many cases are discovered incidentally on imaging. The surgeons also discussed diagnostic strategies for pulmonary nodules and emphasized a patient-tailored approach that balances diagnostic yield with procedural risk. They also acknowledged that emerging modalities, such as liquid biopsy and breath-based DNA detection, are promising but still investigational. They underscored that frailty assessment remains integral to surgical candidacy determination, with both clinical evaluation and pulmonary function testing guiding decision-making. The team also highlighted the role of multidisciplinary tumor boards in integrating surgical, medical, and radiation oncology perspectives. For early-stage disease, surgery remains the standard, whereas patients with stage III disease typically receive neoadjuvant therapy incorporating immuno-oncology agents. The group also discussed expanding surgical indications in select stage IV cases, reflecting improved survival associated with immunotherapy.

In cancer care, ethical challenges rarely come with easy answers.When should treatment stop? How do teams manage moral distress? And what happens when AI begins to shape clinical decisions?In this episode, Dr. Nico Nortjé, Executive Director for the Center for Clinical Ethics in Cancer Care at MD Anderson Cancer Center, joins host Ginger to explore how oncology professionals navigate those moments when medical facts and human emotions collide.Dr. Nortjé shares what he's learned from leading ethics consultations, guiding care teams through end-of-life discussions, moral distress, and the new ethical questions raised by technology.You'll learn:How to recognize and address moral distress before it leads to burnoutHow ethics consults can turn uncertainty into team alignmentHow to approach treatment-limiting conversations with empathyWhat to consider when AI starts influencing care decisionsListen for a grounded, thoughtful look at what ethics really means in oncology today.

AI is changing everything from policy to the patient room. In this AI&H roundtable, Dr. Doug Flora, a leading voice in oncology innovation, joins Dr. Sanjay Juneja, Dr. Debra Patt, and Mika Newton to tackle what's really holding back AI adoption in healthcare. They explore Medicare's AI prior auth model, the role of clinical decision support, and why strong change management is the linchpin of real progress. Dr. Flora shares leadership lessons and insights from the front lines.

Cancer care should be close to home. It's not just convenient, it's necessary for good patient outcomes. We take a closer look at the growing options in the Northland for patients and their families.

A frightening diagnosis can steal the air from a room. Nicole's story gives it back. From the shock of hearing “breast cancer” to the rhythm of surgery, sixteen chemo infusions and now the daily focus of radiation, she lets us into the real work of getting through it: making plans, asking for help and finding bright spots inside the hard days. As a mother of two and a community leader, she talks candidly about fear, the weight of uncertainty and the simple rituals that brought her peace.Those bright spots include a calm, golden-furred constant: April Sweetie, a therapy dog who turns infusion rooms into gentler spaces. With handler Larry, April visits cancer centers, ICUs and children's hospitals, offering a few minutes of ease to patients and the clinicians who care for them. We explore how therapy animals reduce anxiety and boost morale for healthcare teams who often need support as much as the people they treat. April's own journey from a breeding farm to hospital hallways mirrors the transformation that happens when care becomes truly human.For more content from Centra Health check us out on the following channels.YouTubeFacebookInstagramTwitter

Love the episode? Send us a text!Today's episode is going to challenge how you think about treatment. What if cancer care wasn't one-size-fits-all? What if every decision — from the drugs you take to the supplements you choose — was tailored to your own biology?My guest, Dr. John Oertle, Chief Medical Director at Envita Medical Centers, has spent over 25 years pioneering a truly personalized, integrative approach that merges precision oncology, functional medicine, and technology.We'll explore why some people respond to treatment while others don't, what circulating tumor DNA can tell us about recurrence, and how understanding environmental toxins and genetics can literally change your odds.

This episode of Integrative Cancer Solution features an in-depth conversation with Dr. Christina M. Dieli-Conwright, Associate Professor at Dana Farber Harvard Medical School, who specializes in exercise oncology. Christina begins by sharing her unique career path, transitioning from veterinary medicine to clinical exercise physiology, and ultimately focusing her research on the intersection of exercise and cancer care. Her journey highlights the importance of pursuing one's passions and the impact of interdisciplinary expertise in advancing the field of exercise medicine for cancer patients. A significant portion of the episode centers on the physiological benefits of exercise for those living with cancer. Christina notes that exercise plays a crucial role in improving diverse body systems—from cognitive to immune function—and directly enhances quality of life, helps manage treatment side effects, and may even extend survival. She discusses her involvement in the Department of Nutrition, where she helps craft individualized exercise and nutrition strategies tailored to the unique needs of cancer survivors. The discussion highlights how both aerobic and resistance training are vital components of an optimized exercise program for cancer patients. Christina explains the current guidelines, advocating for at least 150 minutes per week of moderate-to-vigorous aerobic activity, complemented by strength training. She stresses, however, that these recommendations should be adapted to each patient's medical history, treatment stage, and overall health status, with frequent assessments to monitor progress and make necessary adjustments. Christina justifies these approaches with evidence from ongoing clinical trials and epidemiological studies, specifically citing strong data supporting exercise benefits for breast and colon cancer survivors. She also addresses the importance of combining exercise with other interventions, such as fasting, to maximize health outcomes and better manage symptoms like fatigue or hormonal imbalance. Despite the positive trends, Christina is candid about research gaps and the need for more precise, personalized guidelines, particularly for less-studied cancers or unique survivor populations. The episode concludes by empowering cancer survivors to seek out reliable resources for exercise guidance—such as the American Cancer Society and the American College of Sports Medicine—and to maintain motivation through personal support networks and physician recommendations. Christina leaves listeners with the message that consistent, individualized exercise is a transformative tool for surviving and thriving beyond cancer, reinforcing the broader theme that exercise is not only safe but essential for improving both the quality and longevity of life for those affected by cancer.Dr. Christina M. Dieli-Conwright explains how individualized exercise prescriptions can improve cognitive, immune, and overall health outcomes for cancer patients.The episode highlights the importance of both aerobic and resistance training, recommending at least 150 minutes per week of moderate-to-vigorous activity for survivors.Combining exercise with strategies like fasting can help manage fatigue and improve glycemic control during cancer therapy.Clinical evidence shows that exercise during and after cancer treatment is linked to better quality of life and potentially higher survival rates, especially for breast and colon cancers.Reliable resources like the American Cancer Society and American College of Sports Medicine provide support for cancer survivors seeking to tailor exercise to their unique needs.____________________________________If you're ready to expand your mind, elevate your health, and awaken your full potential, subscribe now and join the revolution in conscious living with The Dr. K Show!____________________________________CONNECT WITH DR. K: Website: TheKarlfeldtCenter.comWebsite: TrueHealthShow.comInstagram: https://www.instagram.com/thekarlfeldtcenter/The Science and Spirit of Transformation: A Holistic Guide to Elevating Health, Consciousness, and PurposeURL: https://store.thekarlfeldtcenter.com/products/the-science-and-spirit-of-transformation-Price: $24.99-100% Off Discount Code: DRKSHOWPODCAST_____________________________________The Dr. K Show & Integrative Cancer Solutions were created to instill hope and empowerment. Other people have been where you are right now and have already done the research for you. Listen to their stories and journeys and apply what they learned to achieve similar outcomes as they have, cancer remission and an even more fullness of life than before the diagnosis. Guests will discuss what therapies, supplements, and practitioners they relied on to beat cancer. Once diagnosed, time is of the essence. This podcast will dramatically reduce your learning curve as you search for your own solution to cancer. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com____________________________________If you're ready to expand your mind, elevate your health, and awaken your full potential, subscribe now and join the revolution in conscious living with The Dr. K Show!____________________________________CONNECT WITH DR. K: Website: TheKarlfeldtCenter.comWebsite: TrueHealthShow.comInstagram: https://www.instagram.com/thekarlfeldtcenter/The Science and Spirit of Transformation: A Holistic Guide to Elevating Health, Consciousness, and PurposeURL: https://store.thekarlfeldtcenter.com/products/the-science-and-spirit-of-transformation-Price: $24.99-100% Off Discount Code: DRKSHOWPODCAST_____________________________________The Dr. K Show & Integrative Cancer Solutions were created to instill hope and empowerment. Other people have been where you are right now and have already done the research for you. Listen to their stories and journeys and apply what they learned to achieve similar outcomes as they have, cancer remission and an even more fullness of life than before the diagnosis. Guests will discuss what therapies, supplements, and practitioners they relied on to beat cancer. Once diagnosed, time is of the essence. This podcast will dramatically reduce your learning curve as you search for your own solution to cancer. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com

Drs. Ghazal Zandieh, Yash Singh, Thomas DeSilvio, and Brennan Flannery speak with Dr. Joseph Ippolito about how metabolic imaging is transforming cancer diagnosis and treatment through advanced PET and MRI techniques. Together they explore how personalized medicine and sex-specific metabolic differences are reshaping the way radiologists understand and treat glioblastoma. Radiology: Imaging Cancer Journal

Join Dr. Martin in today's episode of The Doctor Is In Podcast.

A tumor that seemed to “smile” back in a flashlight's glare set Jamie Day on a year-long path that tested his body, rewired his priorities, and strengthened every bond that mattered. From the first uneasy swallow after a film festival to the bell that marked the end of treatment, we walk through the raw, funny, and fiercely grateful choices that kept him moving: asking for all the blankets, blasting Mongolian thrash during radiation, and letting two devoted service dogs turn sterile rooms into safe places.HPV-positive squamous cell throat cancer came with good odds and brutal treatment, seven weeks of radiation and chemo that burned, thinned his beard, and made food a battle. Jamie made a decision early: he wouldn't “sad sack” the process. He made the clinic a stage for levity, and the staff met him there. Techs leaned in for the day's soundtrack. Nurses became guides. A nurse advocate unraveled insurance knots at midnight. Front desk faces remembered his name, his jokes, and his dogs. Along the way, he forged symbols to fight by: art of himself on horseback charging the “meatball with tentacles,” a homemade “war hammer,” and the image of two opponents calmly sipping poison until one quits.The through line is simple and strong: choose who you'll be when life breaks, let people help, laugh when you can, and ring the bell for everyone still in the fight. If this story moved you, follow the show, share it with someone who needs a lift, and leave a review with your biggest takeaway so more people can find it.For more content from Centra Health check us out on the following channels.YouTubeFacebookInstagramTwitter

This episode is sponsored by IDEXX This podcast episode, hosted by Adam Christman, DVM, MBA, features oncologists Dana Connell, DVM, MPH, DACVIM (Oncology) and Zachary L. Neumann, DVM, MS, DACVIM (Oncology), discussing the significance of early cancer detection in dogs. The conversation focuses on the IDEXX Cancer Dx testing. The doctors explain how the test, which can be included in routine wellness exams, provides rapid results, enabling veterinarians to make timely diagnoses and improve treatment outcomes. They also touch on the importance of the veterinary team in communicating sensitive news to pet owners and the future potential of the test to screen for other types of cancer.

Behind every oncology referral is a patient—and a family—waiting, hoping, and depending on the system to move fast. In this episode, host Dr. Elizabeth Woodcock, Executive Director of the Patient Access Collaborative, is joined by three oncology access leaders: Kristen Thatcher of The James at Ohio State University, Jennifer Kennedy-Stovall of Duke Cancer Institute, and Kate Healy-Levine of Memorial Sloan Kettering Cancer Center. Together, they explore how leading cancer programs are redefining timely access—balancing urgency with empathy, operational efficiency with equity, and data with culture.Tune in to hear how these systems are tackling workforce constraints, leveraging APPs, and redesigning scheduling models to ensure that every patient receives the right care, at the right time.Topics include culture and urgency in access, diagnostic and APP models, template standardization, financial navigation, and equity in oncology care.

Live this week from the ACCC's 42nd National Oncology Conference (NOC), CANCER BUZZ speaks with ACCC Executive Director Meagan O'Neill, MS, who previews the week.  Guest:  Meagan O'Neill, MS Executive Director, Association of Cancer Care Centers   Resources:  ACCC 42nd National Oncology Conference Agenda  

Since 2010, the Association of Cancer Care Centers (ACCC) has produced an annual Trending Now in Cancer Care report, highlighting the biggest challenges, solutions, and opportunities in oncology. In this episode, CANCER BUZZ speaks with Lindsey Causey, DNP, APRN, ANP-BC, AOCNP, nurse practitioner at Cone Health Cancer Center, about part 2 of the 2025 trend report. She shares takeaways from the in-person discussions at the ACCC Annual Meeting & Cancer Center Business Summit (AMCCBS) that informed this report, as well as how she uses the information from ACCC's trend reports at her own cancer center. Part 2 of the 2025 Trending Now in Cancer Care report focuses on payer-driven challenges and solutions, comprehensive cancer care services, research and clinical trials, and mobile screening to engage communities in cancer prevention and education. The full article can be found in Oncology Issues, the official journal of ACCC. Lindsey Causey, DNP, APRN, ANP-BC, AOCNP Nurse Practitioner Cone Health Cancer Center Greensboro, NC “Many patients come into my clinic and they say, I just feel like a piece of me goes to one office, a piece of me goes to another office. I don't want to be seen as pieces of a whole person. I want to be seen as the whole person and know what to do and feel like I have all my answers in one place. “ “[The trend report] really allows you to reflect on what the current state is first and then understand what might need to happen to be able to bring some of these things to fruition.” “Early palliative care is essential, not just because it helps with patients and improving their symptoms and wellbeing, it also increases their survival, but it can also help reduce provider burnout by partnering with palliative care.” Resources: 2025 Trending Now in Cancer Care: Part 1 2025 Trending Now in Cancer Care: Part 2 Archived Reports CANCERBUZZ episode: 2025 Trending Now in Cancer Care: Part 1  

Approximately one in four people will face a cancer diagnosis. For most, the hardest part won't be the treatment itself but the waiting, the 3 AM questions, the logistical maze of care coordination that can mean the difference between hope and despair. Ann Stadjuhar knows this truth from both sides of the stethoscope. When Ann navigated her own cancer diagnosis, she had every advantage: 20 years of healthcare expertise, knowledge of case volumes, connections to top surgeons at Optum. Yet even she found the system overwhelming. Her uncle in rural New Mexico wasn't as fortunate; by the time he reached MD Anderson, inadequate local care had sealed his fate. These parallel experiences crystallized Ann's mission at Reimagine Care: ensuring no one faces cancer alone, regardless of their zip code or insider knowledge. This conversation comes at a critical moment. As cancer increasingly strikes younger populations, with many cancers now appearing in people's 20s and 30s rather than their 50s, we need innovators who understand that technology without empathy is just expensive machinery. Ann represents a new breed of healthcare leaders who see AI not as a replacement for human connection, but as a way to multiply it. "The worst part of cancer is the wait," Ann explains. "We can be there 24/7 to understand whether there may be social determinants of health needs. I need a ride to treatment. I need someone to watch my dog. I have issues paying my electric bill. Sometimes people are honestly more comfortable telling the bot they're having these challenges." After two decades revolutionizing digital health from women's health to pandemic response centers, Ann calls cancer care her "capstone." She's witnessed how the 18-month health system adoption cycle literally costs lives. Now, armed with Meta glasses and AI tools that multiply her capabilities "times four," she's racing against a broken system where your uncle's zip code shouldn't determine whether his cancer stays operable. In this episode of Inspiring Women with Laurie McGraw, discover how one woman's journey through cancer transformed into a mission to democratize access to the kind of insider knowledge that can save lives. From the Cancer X Accelerator to Reimagine Care's AI companion REMI, Ann reveals why the future of cancer care isn't about choosing between humans and machines. It's about creating technology sophisticated enough to know that sometimes, the most advanced intervention is simply helping someone find a dog sitter so they don't miss chemotherapy. For Ann Stadjuhar, reimagining cancer care isn't about replacing human connection. It's about multiplying it. In a healthcare system where staying curious might be the difference between innovation and stagnation, between treatment and tragedy, she's proof that the most powerful technology is the kind that remembers to be human. Key Insights: Why patients confess more to AI than to their doctors, and what that means for care How social determinants of health become matters of life and death in cancer treatment The hidden complexities even healthcare insiders struggle to navigate Why the next generation needs emotional intelligence more than technical skills How one woman's cancer diagnosis became a blueprint for system-wide change About the Guest:  Ann Stadjuhar brings 20+ years of digital health innovation to her role as Chief Growth Officer at Reimagine Care. From launching pharmaceuticals to scaling population health tools, she's run what she calls "the gauntlet" of healthcare transformation. Her personal cancer journey while at Optum revealed the gaps even insiders face, inspiring her mission to ensure 24/7 companionship for every cancer patient through AI-powered human care. Guest & Host Links Connect with Laurie McGraw on LinkedIn Connect with Ann Stadjuhar on LinkedIn Connect with Inspiring Women Browse Episodes | LinkedIn | Instagram | Apple | Spotify